Drugs / ERAS-601
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04959981 | Sep 2021 → Apr 2023 | non-small cell lung carcinoma | Erasca, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04670679 | Dec 2020 → Feb 2026 overdue | — | Erasca, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06957327 | Apr 2025 → Apr 2027 expected | chordoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05279859 | Mar 2022 → Mar 2025 | acute myeloid leukemia | Erasca, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04866134 | May 2021 → Nov 2026 expected | — | Erasca, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERAS-601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04959981 ↗ |
| Action | Inhibit | “ERAS-601 SHP2 Inhibitor” NCT04670679 ↗ |
| Route | Oral | “Administered orally” NCT04670679 ↗ |